Neuralstem to Participate at Upcoming Investor Conferences
12 March 2018 - 10:00PM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that members of the management team will participate at
the following upcoming investor conferences:
- B. Riley FBR, Inc. & Co. China Healthcare Investment &
Partnering Symposium in Hangzhou, China, on Saturday, March 17 at
9:00am China Standard Time. A live audio webcast of this
presentation will be available in the Investors section of the
Company's website at investor.neuralstem.com. The webcast will be
archived on the Company's website for 90 days following the
presentation.
- 15th Annual BIO Asia International Conference in Tokyo, Japan.
Rich Daly, Neuralstem’s President & CEO, will participate in a
panel discussion entitled, “Lessons on Biopharma Partnerships with
Universities” on Tuesday, March 20 at 9:00am Japan Standard
Time.
- Also at the 15th Annual BIO Asia Conference, Dr. Karl Johe,
PhD, Chief Scientific Officer of Neuralstem, will provide an update
on NSI-566, the Company’s lead cell therapy candidate, in a
presentation on Monday, March 19 at 5:30pm Japan Standard
Time.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. The Company has two lead development
candidates:
- NSI-189, is a small molecule in clinical development for major
depressive disorder (MDD) and in preclinical development for
Angelman syndrome, irradiation-induced cognitive impairment, Type 1
and Type 2 diabetes, and stroke.
- NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and
chronic spinal cord injury (cSCI).
Neuralstem’s diversified portfolio of product candidates is
based on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward
Looking Information
This news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three and nine
months ended September 30, 2017, filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902kimberly@argotpartners.com
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Apr 2024 to May 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Neuralstem Inc (NASDAQ): 0 recent articles
More News Articles